Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Aug 16;83(5):588–593. doi: 10.1054/bjoc.2000.1316

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

W K A Yung 1, R E Albright 2, J Olson 3, R Fredericks 4, K Fink 5, M D Prados 6, M Brada 7, A Spence 8, R J Hohl 9, W Shapiro 10, M Glantz 11, H Greenberg 12, R G Selker 13, N A Vick 14, R Rampling 15, H Friedman 16, P Phillips 17, J Bruner 1, N Yue 18, D Osoba 19, S Zaknoen 20, V A Levin 1
PMCID: PMC2363506  PMID: 10944597

Abstract

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m2/day or 150 mg/m2/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m2/day or 125 mg/m2/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity. © 2000 Cancer Research Campaign

Keywords: malignant glioma, temozolomide, procarbazine, glioblastoma multiforme

Full Text

The Full Text of this article is available as a PDF (99.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaronson N. K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N. J., Filiberti A., Flechtner H., Fleishman S. B., de Haes J. C. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365–376. doi: 10.1093/jnci/85.5.365. [DOI] [PubMed] [Google Scholar]
  2. Bleehen N. M., Newlands E. S., Lee S. M., Thatcher N., Selby P., Calvert A. H., Rustin G. J., Brampton M., Stevens M. F. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995 Apr;13(4):910–913. doi: 10.1200/JCO.1995.13.4.910. [DOI] [PubMed] [Google Scholar]
  3. Bower M., Newlands E. S., Bleehen N. M., Brada M., Begent R. J., Calvert H., Colquhoun I., Lewis P., Brampton M. H. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997;40(6):484–488. doi: 10.1007/s002800050691. [DOI] [PubMed] [Google Scholar]
  4. Burger P. C., Vogel F. S., Green S. B., Strike T. A. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer. 1985 Sep 1;56(5):1106–1111. doi: 10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  5. Chamberlain M. C., Kormanik P. A. Practical guidelines for the treatment of malignant gliomas. West J Med. 1998 Feb;168(2):114–120. [PMC free article] [PubMed] [Google Scholar]
  6. Feun L. G., Savaraj N., Landy H. J. Drug resistance in brain tumors. J Neurooncol. 1994;20(2):165–176. doi: 10.1007/BF01052726. [DOI] [PubMed] [Google Scholar]
  7. Fine H. A., Dear K. B., Loeffler J. S., Black P. M., Canellos G. P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993 Apr 15;71(8):2585–2597. doi: 10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  8. Forsyth P. A., Cairncross J. G. Chemotherapy for malignant gliomas. Baillieres Clin Neurol. 1996 Jun;5(2):371–393. [PubMed] [Google Scholar]
  9. Jaeschke R., Singer J., Guyatt G. H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989 Dec;10(4):407–415. doi: 10.1016/0197-2456(89)90005-6. [DOI] [PubMed] [Google Scholar]
  10. Juniper E. F., Guyatt G. H., Willan A., Griffith L. E. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994 Jan;47(1):81–87. doi: 10.1016/0895-4356(94)90036-1. [DOI] [PubMed] [Google Scholar]
  11. King M. T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996 Dec;5(6):555–567. doi: 10.1007/BF00439229. [DOI] [PubMed] [Google Scholar]
  12. McComb R. D., Burger P. C. Pathologic analysis of primary brain tumors. Neurol Clin. 1985 Nov;3(4):711–728. [PubMed] [Google Scholar]
  13. Newlands E. S., Blackledge G. R., Slack J. A., Rustin G. J., Smith D. B., Stuart N. S., Quarterman C. P., Hoffman R., Stevens M. F., Brampton M. H. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992 Feb;65(2):287–291. doi: 10.1038/bjc.1992.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Newlands E. S., O'Reilly S. M., Glaser M. G., Bower M., Evans H., Brock C., Brampton M. H., Colquhoun I., Lewis P., Rice-Edwards J. M. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996 Dec;32A(13):2236–2241. doi: 10.1016/s0959-8049(96)00258-4. [DOI] [PubMed] [Google Scholar]
  15. Newton H. B., Junck L., Bromberg J., Page M. A., Greenberg H. S. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology. 1990 Nov;40(11):1743–1746. doi: 10.1212/wnl.40.11.1743. [DOI] [PubMed] [Google Scholar]
  16. O'Reilly S. M., Newlands E. S., Glaser M. G., Brampton M., Rice-Edwards J. M., Illingworth R. D., Richards P. G., Kennard C., Colquhoun I. R., Lewis P. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A(7):940–942. doi: 10.1016/s0959-8049(05)80198-4. [DOI] [PubMed] [Google Scholar]
  17. Osoba D., Aaronson N. K., Muller M., Sneeuw K., Hsu M. A., Yung W. K., Brada M., Newlands E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996 Feb;5(1):139–150. doi: 10.1007/BF00435979. [DOI] [PubMed] [Google Scholar]
  18. Osoba D., Aaronson N., Zee B., Sprangers M., te Velde A. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res. 1997 Mar;6(2):103–108. doi: 10.1023/a:1026429831234. [DOI] [PubMed] [Google Scholar]
  19. Osoba D., Rodrigues G., Myles J., Zee B., Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998 Jan;16(1):139–144. doi: 10.1200/JCO.1998.16.1.139. [DOI] [PubMed] [Google Scholar]
  20. Rodriguez L. A., Prados M., Silver P., Levin V. A. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer. 1989 Dec 15;64(12):2420–2423. doi: 10.1002/1097-0142(19891215)64:12<2420::aid-cncr2820641204>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  21. Stevens M. F., Hickman J. A., Langdon S. P., Chubb D., Vickers L., Stone R., Baig G., Goddard C., Gibson N. W., Slack J. A. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987 Nov 15;47(22):5846–5852. [PubMed] [Google Scholar]
  22. Tsang L. L., Farmer P. B., Gescher A., Slack J. A. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol. 1990;26(6):429–436. doi: 10.1007/BF02994094. [DOI] [PubMed] [Google Scholar]
  23. Vasantha Kumar A. R., Renaudin J., Wilson C. B., Boldrey E. B., Enot K. J., Levin V. A. Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study. J Neurosurg. 1974 Mar;40(3):365–371. doi: 10.3171/jns.1974.40.3.0365. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES